GSA Capital Partners’s 10x Genomics TXG Stock Holding History

GSA Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$591K	Buy	+15,404	New	+$404K	0.04%	885
2026 Q1	–	Sell	-18,931	Closed	-$309K	–	2172
2025 Q4	$309K	Sell	18,931 -102,213	-84%	-$1.54M	0.03%	1158
2025 Q3	$1.42M	Buy	121,144 +106,167	+709%	+$1.38M	0.12%	209
2025 Q2	$173K	Sell	14,977 -32,776	-69%	-$299K	0.01%	1540
2025 Q1	$417K	Buy	47,753 +16,831	+54%	+$212K	0.04%	925
2024 Q4	$444K	Buy	+30,922	New	+$488K	0.03%	977
2023 Q4	–	Sell	-47,664	Closed	-$1.97M	–	1942
2023 Q3	$1.97M	Buy	47,664 +39,158	+460%	+$2.04M	0.17%	112
2023 Q2	$475K	Buy	+8,506	New	+$460K	0.05%	775
2023 Q1	–	Sell	-18,550	Closed	-$676K	–	1945
2022 Q4	$676K	Buy	+18,550	New	+$607K	0.08%	418
2021 Q3	–	Sell	-1,798	Closed	-$352K	–	1781
2021 Q2	$352K	Buy	+1,798	New	+$325K	0.04%	841
2021 Q1	–	Sell	-1,888	Closed	-$267K	–	1504
2020 Q4	$267K	Buy	1,888 +238	+14%	+$34.5K	0.04%	810
2020 Q3	$206K	Buy	+1,650	New	+$173K	0.03%	993

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's TXG Position: Q2 2026 in Review

GSA Capital Partners opened a new position in 10x Genomics (TXG) in Q2 2026: 15,404 shares worth $591K. The stake represents 0.04% of the portfolio and ranks #885 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TXG as recently as Q4 2025.

GSA Capital Partners first reported a position in TXG in Q3 2020 and has held it in 12 quarters since. The position peaked at $1.97M in Q3 2023. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

GSA Capital Partners held 15,404 shares of 10x Genomics worth $591K as of Q2 2026.
10x Genomics was a new GSA Capital Partners position in Q2 2026.
10x Genomics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #885 holding.
GSA Capital Partners first reported a position in 10x Genomics in Q3 2020 and has held it in 12 quarters since.
GSA Capital Partners's 10x Genomics position peaked at $1.97M in Q3 2023.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.